USPTO Trademark Application for NYCELSIO - Cell Therapy
Summary
The USPTO has received an intent-to-use trademark application (TM99155730) from NYCELSIO for services related to cell therapy and immunotherapy. The application covers pharmaceutical preparations and medical treatment services, including specific immunotherapy procedures.
What changed
The United States Patent and Trademark Office (USPTO) has recorded an intent-to-use trademark application (TM99155730) filed on April 25, 2025, by NYCELSIO. The application seeks to protect trademarks for a range of cell therapy and immunotherapy products and services, including pharmaceutical preparations for cancer treatment, engineered T-cell receptors, and specific medical treatment services involving cell harvesting, modification, and infusion.
This filing indicates NYCELSIO's intention to commercialize these advanced therapies. While this is a trademark application and not a regulatory approval for the therapies themselves, it signals a significant step in the company's market entry strategy. Compliance officers in the pharmaceutical and healthcare sectors should note this development as it pertains to the branding and commercialization of novel cell-based treatments.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
← USPTO Trademark Applications
NYCELSIO
Intent to Use TM99155730 Kind: intenttouse Mar 24, 2026
Abstract
Cell therapy pharmaceutical preparations; immunotherapy preparations for use in cancer treatment; T-cell receptors in the nature of pharmaceutical preparations for use in cancer treatment; pharmaceutical immunotherapy preparations comprising engineered T-cell receptors for use in cancer treatment; pharmaceutical immunotherapy preparations comprising genes encoding engineered T-cell receptors for use in cancer treatment; Cell therapy medical treatment services; medical services, namely, immunotherapy services; medical services, namely, medical treatment and immune-therapy comprising harvesting a patient's white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient
Filing Date
2025-04-25
Related changes
Get daily alerts for USPTO Trademarks - Medical Services (Class 044)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Trademarks - Medical Services (Class 044) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.